Table 18.
Representative clinical trials of the combination therapy of anti-angiogenesis and immune checkpoint blockade
| Combination strategy | NCT number | Cancer types | Phases | Status |
|---|---|---|---|---|
| Atezolizumab combined with Bevacizumab | NCT05063552 | HNSCC | II/III | Recruiting |
| NCT02366143 | NSCLC | III | Completed | |
| NCT04732598 | Breast Cancer | III | Active, not recruiting | |
| NCT03038100 | Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | III | Completed | |
| NCT03353831 | Ovarian Cancer | III | Active, not recruiting | |
| NCT02997228 | Colorectal Adenocarcinoma | III | Recruiting | |
| NCT05665348 | HCC | II/III | Not yet recruiting | |
| NCT03991403 | NSCLC | III | Active, not recruiting | |
| NCT04194203 | NSCLC | III | Active, not recruiting | |
| NCT03434379 | HCC | III | Completed | |
| NCT04487067 | HCC | III | Active, not recruiting | |
| NCT03693573 | RCC | III | Withdrawn | |
| NCT05904886 | HCC | III | Recruiting | |
| NCT02420821 | RCC | III | Completed | |
| NCT04803994 | HCC | III | Recruiting | |
| NCT04732286 | HCC | III | Active, not recruiting | |
| NCT04712643 | HCC | III | Active, not recruiting | |
| NCT04102098 | HCC | III | Active, not recruiting | |
| NCT03556839 | Cervical Cancer | III | Active, not recruiting | |
| Axitinib Combined with Avelumab | NCT03013946 | RCC | III | Recruiting |
| NCT03472560 | NSCLC and Urothelial Cancer | II | Terminated | |
| NCT02912572 | Endometrial Cancer | II | Active, not recruiting | |
| NCT04258956 | Gastrointestinal Stromal Tumors | II | Unknown status | |
| NCT02684006 | RCC | III | Active, not recruiting | |
| NCT03386929 | NSCLC | I/II | Terminated | |
| NCT04562441 | NPC | II | Active, not recruiting | |
| NCT04698213 | RCC | II | Recruiting | |
| NCT05327686 | RCC | II | Recruiting | |
| NCT03990571 | Adenoid Cystic Carcinoma | II | Completed | |
| NCT03341845 | RCC | II | Recruiting | |
| NCT03291314 | Recurrent Glioblastoma | II | Completed | |
| NCT05176288 | ccRCC | II | Withdrawn | |
| NCT05249569 | HCC | II | Terminated | |
| Pembrolizumab Combined With Lenvatinib | NCT04676412 | NSCLC | III | Active, not recruiting |
| NCT03829332 | NSCLC | III | Active, not recruiting | |
| NCT04716933 | NSCLC | III | Active, not recruiting | |
| NCT03829319 | NSCLC | III | Active, not recruiting | |
| NCT03976375 | NSCLC | III | Active, not recruiting | |
| NCT03898180 | Urothelial Carcinoma | III | Active, not recruiting | |
| NCT03517449 | Endometrial Neoplasms | III | Active, not recruiting | |
| NCT04776148 | Colorectal Neoplasms | III | Active, not recruiting | |
| NCT04949256 | Esophageal Carcinoma | III | Recruiting | |
| NCT05077215 | Endometrial Cancer | III | Not yet recruiting | |
| NCT04865289 | Endometrial Cancer | III | Active, not recruiting | |
| NCT03884101 | Endometrial Cancer | III | Active, not recruiting | |
| NCT03486873 | Solid and Hematologic Malignancies | III | Recruiting | |
| NCT04889118 | Melanoma | III | Active, not recruiting | |
| NCT03820986 | Melanoma | III | Active, not recruiting | |
| NCT05899049 | RCC | III | Recruiting | |
| NCT04736706 | RCC | III | Recruiting | |
| NCT04662710 | Gastroesophageal Adenocarcinoma | III | Active, not recruiting | |
| NCT05523323 | HNSCC | III | Active, not recruiting | |
| NCT04199104 | HNSCC | III | Active, not recruiting | |
| NCT03713593 | HCC | III | Active, not recruiting | |
| NCT04246177 | HCC | III | Active, not recruiting | |
| NCT02811861 | RCC | III | Active, not recruiting | |
| SHR-1210 Combined with Apatinib | NCT03813784 | Gastric Cancer | III | Unknown status |
| NCT04335006 | TNBC | III | Terminated | |
| NCT04342910 | Gastric Cancer | III | Unknown status | |
| NCT05049681 | Esophageal Cancer | III | Unknown status | |
| Nivolumab Combined with Sitravatinib | NCT03906071 | NSCLC | III | Active, not recruiting |
| NCT03015740 | Kidney Cancer | I/II | Completed | |
| NCT04904302 | ccRCC | II | Active, not recruiting | |
| NCT02954991 | NSCLC | II | Completed | |
| NCT04887870 | Solid Malignancies | II/III | Enrolling by invitation | |
| NCT03606174 | Urothelial Carcinoma | II | Terminated | |
| NCT03680521 | ccRCC | II | Completed |
Note: HNSCC head and neck squamous cell carcinoma, NSCLC non-small-cell lung cancer, HCC hepatocellular carcinoma, RCC renal cell carcinoma, ccRCC clear cell renal cell cancer, NPC nasopharyngeal carcinoma, TNBC triple-negative breast cancer